p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns

[1]  S. Leung,et al.  International Endocervical Adenocarcinoma Criteria and Classification (IECC): An Independent Cohort With Clinical and Molecular Findings , 2021, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[2]  C. Gilks,et al.  Performance of the pattern‐based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma , 2020, Histopathology.

[3]  D. Huntsman,et al.  Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status , 2020, Modern Pathology.

[4]  USCAP 2020 Abstracts: Index of Abstract Authors , 2020, Modern Pathology.

[5]  C. Gilks,et al.  Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts , 2020, Histopathology.

[6]  S. Leung,et al.  Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma , 2019, International Journal of Gynecological Cancer.

[7]  D. Huntsman,et al.  c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract , 2019, The American journal of surgical pathology.

[8]  E. Oliva,et al.  Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC) , 2019, The American journal of surgical pathology.

[9]  M. Köbel,et al.  Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[10]  M. Pike,et al.  Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas , 2018, The American journal of surgical pathology.

[11]  A. Lapuk,et al.  Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice , 2018, PloS one.

[12]  M. Pike,et al.  International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix , 2018, The American journal of surgical pathology.

[13]  J. Ordi,et al.  Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance , 2017, Clinical Cancer Research.

[14]  A. Talhouk,et al.  Human papillomavirus (HPV)‐independent vulvar squamous cell carcinoma has a worse prognosis than HPV‐associated disease: a retrospective cohort study , 2017, Histopathology.

[15]  P. Catalano,et al.  Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. , 2016, Gynecologic oncology.

[16]  N. Rosenfeld,et al.  Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma , 2016, The journal of pathology. Clinical research.

[17]  F. Lucas,et al.  Biomarkers p16, Human Papillomavirus and p53 Predict Recurrence and Survival in Early Stage Squamous Cell Carcinoma of the Vulva , 2016, Journal of lower genital tract disease.

[18]  J. McAlpine,et al.  p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[19]  R. Murali,et al.  Squamous precursor lesions of the vulva: current classification and diagnostic challenges. , 2016, Pathology.

[20]  M. Pike,et al.  Gastric-type Endocervical Adenocarcinoma: An Aggressive Tumor With Unusual Metastatic Patterns and Poor Prognosis , 2015, The American journal of surgical pathology.

[21]  E. Oliva,et al.  Squamous Cell Carcinoma of the Vulva: A Subclassification of 97 Cases by Clinicopathologic, Immunohistochemical, and Molecular Features (p16, p53, and EGFR) , 2015, The American journal of surgical pathology.

[22]  J. Ordi,et al.  HPV‐negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis , 2015, BJOG : an international journal of obstetrics and gynaecology.

[23]  R. Kurman,et al.  WHO classification of tumours of female reproductive organs , 2014 .

[24]  M. Henry,et al.  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology , 2012, Archives of pathology & laboratory medicine.

[25]  I. Shih,et al.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis , 2011, Modern Pathology.

[26]  B. Lloveras,et al.  HPV-negative Vulvar Intraepithelial Neoplasia (VIN) With Basaloid Histologic Pattern: An Unrecognized Variant of Simplex (Differentiated) VIN , 2009, The American journal of surgical pathology.

[27]  E. Campo,et al.  p16 Overexpression Identifies HPV-positive Vulvar Squamous Cell Carcinomas , 2006, The American journal of surgical pathology.

[28]  Michelle S. Longworth,et al.  Pathogenesis of Human Papillomaviruses in Differentiating Epithelia , 2004, Microbiology and Molecular Biology Reviews.

[29]  C. Meijer,et al.  The presence of high‐risk HPV combined with specific p53 and p16INK4a expression patterns points to high‐risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix , 2003, The Journal of pathology.

[30]  P. Clement,et al.  Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis , 2002, Histopathology.

[31]  E. Tschachler,et al.  Absence of p53 protein overexpression in precancerous lesions of the vulva , 1998, Cancer.

[32]  F. Rilke,et al.  Papillomavirus, p53 Alteration, and Primary Carcinoma of the Vulva , 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[33]  F. Rilke,et al.  Papillomavirus, p53 alteration and primary carcinoma of the vulva. , 1995, European journal of cancer.

[34]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[35]  J. Schiller,et al.  Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes , 1992, Journal of virology.

[36]  J. Minna,et al.  Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins , 1992, Journal of virology.

[37]  K. Shah,et al.  Probable Nonpapiilomavirus Etiology of Squamous Cell Carcinoma of the Vulva in Older Women: A Clinicopathologic Study Using In Situ Hybridization and Polymerase Chain Reaction , 1991 .

[38]  K. Shah,et al.  Probable Nonpapillomavirus Etiology of Squamous Cell Carcinoma of the Vulva in Older Women: A Clinicopathologic Study Using In Situ Hybridization and Polymerase Chain Reaction , 1991, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[39]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.